Results 41 to 50 of about 113,089 (165)

Profiles of peripheral B cell subsets in a cohort of primary Sjögren's syndrome patients and their potential clinical significance

Journal of Dental Sciences
Background/purpose: Primary Sjögren's syndrome is a prototypical autoimmune disease, with B cell dysfunction as a dominant feature. Further insights into distribution of B cell subsets in primary Sjögren's syndrome are urgently required to identify the ...
Yixiao Xing, Boya Li, Pan Wei, Hong Hua
doaj   +1 more source

CD19 CAR T Cells

Cell, 2017
CARs are synthetic receptors that reprogram immune cells for therapeutic purposes. They comprise three canonical domains for antigen recognition, T cell activation, and costimulation. The CAR cDNA is genetically integrated in the T cell genome. Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient ...
openaire   +2 more sources

In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine

eJHaem
CD19‐targeting treatments have shown promise in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Loncastuximab tesirine (loncastuximab tesirine‐lpyl [Lonca]) is a CD19‐targeting antibody‐drug conjugate indicated for R/R DLBCL after at ...
Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo‐Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Danilo Cucchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni   +12 more
doaj   +1 more source

Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals

Frontiers in Immunology
BackgroundChimeric antigen receptor (CAR) engineered natural killer (NK) cells exhibit advantages such as MHC-independent recognition and strong anti-tumor functions.
Qi Zhang, Chengxiang Xia, Qitong Weng, Leqiang Zhang, Yao Wang, Yanhong Liu, Xiujuan Zheng, Yunqing Lin, Yi Chen, Yiyuan Shen, Hanmeng Qi, Lijuan Liu, Yanping Zhu, Min Zhang, Dehao Huang, Fangxiao Hu, Mengyun Zhang, Mengyun Zhang, Hui Zeng, Jinyong Wang, Jinyong Wang, Tongjie Wang, Tongjie Wang   +22 more
doaj   +1 more source

Phenotyping of P105-Negative B Cell Subsets in Patients with Systemic Lupus Erythematosus

Clinical and Developmental Immunology, 2012
This study aimed to investigate phenotype of RP105(−) B cell subsets in patients with systemic lupus erythematosus (SLE). Flow cytometry was used for phenotyping RP105-negaive B cell subsets.
Syuichi Koarada, Yoshifumi Tada, Rie Suematsu, Sachiko Soejima, Hisako Inoue, Akihide Ohta, Kohei Nagasawa   +6 more
doaj   +1 more source

A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies

Clinical & Translational Immunology
Objectives To evaluate the manufacturability, efficacy and safety of allogeneic CD19 chimeric antigen receptor double‐negative T cells (CD19‐CAR‐DNTs) as an off‐the‐shelf therapeutic cell product.
Dan Wang, Liuyang Wang, Shuai Liu, Jianjun Tong, Honglin Zhu, Man Xu, Xiancai Li, Zhiqiang Xiang, Qinghua Sun, Hengcai Wang, Yuli Wang, Shuyang Wang, Liming Yang   +12 more
doaj   +1 more source

CD19 [PDF]

Science-Business eXchange, 2009
openaire   +2 more sources

Optimization of preparation method and specificity verification of cat CD19 monoclonal antibody for disease diagnosis and treatment

Heliyon
CD19 is a surface antigen on B cells that regulates B cell activation and proliferation, participating in B cell signaling. It is expressed in all B cell lineage tumor diseases, making CD19 a significant marker for detecting B cell tumor diseases and an ...
Liya Shen, Shuqi Yan, Aoyu Xu, Di Lan, Xue Jiang, Yuehan Peng, Songjun Wang, Zhanzhong Wang, Yongyan Chen   +8 more
doaj   +1 more source

CD19 [PDF]

, 2019
H. Renz, B. Gierten
openaire   +1 more source

Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL

Frontiers in Immunology
IntroductionChimeric antigen receptor (CAR) T-cell therapies have achieved remarkable success in treating B-cell malignancies, including acute lymphoblastic leukemia (B-ALL).
Jennifer Bolsée, Benjamin Violle, Céline Jacques-Hespel, Thuy Nguyen, Caroline Lonez, Eytan Breman   +5 more
doaj   +1 more source